{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:31:56Z","timestamp":1793680316603,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11606-022-07939-x","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T20:05:14Z","timestamp":1668801914000},"page":"799-803","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Envisioning Minimally Disruptive Opioid Use Disorder Care"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-2041","authenticated-orcid":false,"given":"Honora","family":"Englander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena A.","family":"Levander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"7939_CR1","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","volume":"70","author":"JTL O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell J TL, Gladden RM, Davis NL, Bitting J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls \u2014 United States, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70:1740-1746. https:\/\/doi.org\/10.15585\/mmwr.mm7050e3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7939_CR2","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Rivera BD, Jent V, Keyes KM, Jones CM, Cerd\u00e1 M. Has the treatment gap for opioid use disorder narrowed in the U.S.?: a yearly assessment from 2010 to 2019. Int J Drug Policy. 2022:103786. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103786","DOI":"10.1016\/j.drugpo.2022.103786"},{"key":"7939_CR3","unstructured":"National Academies of Sciences, Engineering, Medicine. Methadone Treatment for Opioid Use Disorder: Improving Access through Regulatory and Legal Change: Proceedings of a Workshop. The National Academies Press; 2022:180."},{"issue":"S2","key":"7939_CR4","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/ajph.2021.306665","volume":"112","author":"C Simon","year":"2022","unstructured":"Simon C, Vincent L, Coulter A, et al. The Methadone Manifesto: treatment experiences and policy recommendations from methadone patient activists. Am J Public Health. 2022;112(S2):S117-s122. https:\/\/doi.org\/10.2105\/ajph.2021.306665","journal-title":"Am J Public Health."},{"issue":"1","key":"7939_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \"It's like 'liquid handcuffs\": the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients' lives. Harm Reduct J. 2021;18(1):88. https:\/\/doi.org\/10.1186\/s12954-021-00535-y","journal-title":"Harm Reduct J"},{"issue":"1","key":"7939_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/healthcare3010050","volume":"3","author":"AL Leppin","year":"2015","unstructured":"Leppin AL, Montori VM, Gionfriddo MR. Minimally disruptive medicine: a pragmatically comprehensive model for delivering care to patients with multiple chronic conditions. Healthcare (Basel). 2015;3(1):50-63. https:\/\/doi.org\/10.3390\/healthcare3010050","journal-title":"Healthcare (Basel)"},{"issue":"11","key":"7939_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11892-017-0935-7","volume":"17","author":"V Serrano","year":"2017","unstructured":"Serrano V, Spencer-Bonilla G, Boehmer KR, Montori VM. Minimally disruptive medicine for patients with diabetes. Curr Diab Rep. 2017;17(11):104. https:\/\/doi.org\/10.1007\/s11892-017-0935-7","journal-title":"Curr Diab Rep"},{"issue":"10","key":"7939_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240516","volume":"15","author":"TK Corbett","year":"2020","unstructured":"Corbett TK, Cummings A, Lee K, et al. Planning and optimising CHAT&PLAN: a conversation-based intervention to promote person-centred care for older people living with multimorbidity. PLoS One. 2020;15(10):e0240516. https:\/\/doi.org\/10.1371\/journal.pone.0240516","journal-title":"PLoS One."},{"issue":"7","key":"7939_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamainternmed.2014.1608","volume":"174","author":"AL Leppin","year":"2014","unstructured":"Leppin AL, Gionfriddo MR, Kessler M, et al. Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials. JAMA Intern Med. 2014;174(7):1095-107. https:\/\/doi.org\/10.1001\/jamainternmed.2014.1608","journal-title":"JAMA Intern Med."},{"issue":"10","key":"7939_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s11606-017-4117-8","volume":"32","author":"G Spencer-Bonilla","year":"2017","unstructured":"Spencer-Bonilla G, Qui\u00f1ones AR, Montori VM. Assessing the burden of treatment. J Gen Intern Med. 2017;32(10):1141-1145. https:\/\/doi.org\/10.1007\/s11606-017-4117-8","journal-title":"J Gen Intern Med."},{"issue":"1","key":"7939_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15256\/joc.2016.6.73","volume":"6","author":"T Albreht","year":"2016","unstructured":"Albreht T, Dyakova M, Schellevis FG, Van den Broucke S. Many diseases, one model of care? J Comorb. 2016;6(1):12-20. https:\/\/doi.org\/10.15256\/joc.2016.6.73","journal-title":"J Comorb."},{"issue":"1","key":"7939_CR12","doi-asserted-by":"publisher","first-page":"e13763","DOI":"10.2196\/13763","volume":"12","author":"TH Wieringa","year":"2020","unstructured":"Wieringa TH, Sanchez-Herrera MF, Espinoza NR, Tran VT, Boehmer K. Crafting care that fits: workload and capacity assessments complementing decision aids in implementing shared decision making. J Particip Med. 2020;12(1):e13763. https:\/\/doi.org\/10.2196\/13763","journal-title":"J Particip Med"},{"issue":"6","key":"7939_CR13","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamaoncol.2021.0952","volume":"7","author":"GB Taksler","year":"2021","unstructured":"Taksler GB, Peterse EFP, Willems I, et al. Modeling strategies to optimize cancer screening in USPSTF guideline-noncompliant women. JAMA Oncol. 2021;7(6):885-894. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0952","journal-title":"JAMA Oncol"},{"key":"7939_CR14","doi-asserted-by":"publisher","unstructured":"Ekstedt M, Kirsebom M, Lindqvist G, et al. Design and development of an eHealth service for collaborative self-management among older adults with chronic diseases: a theory-driven user-centered approach. Int J Environ Res Public Health. 2021;19(1) https:\/\/doi.org\/10.3390\/ijerph19010391","DOI":"10.3390\/ijerph19010391"},{"key":"7939_CR15","doi-asserted-by":"publisher","unstructured":"Abu Dabrh AM, Boehmer KR, Shippee N, et al. Minimally disruptive medicine (MDM) in clinical practice: a qualitative case study of the human immunodeficiency virus (HIV) clinic care model. BMC Health Serv Res. 2021;21(1):24. https:\/\/doi.org\/10.1186\/s12913-020-06010-x","DOI":"10.1186\/s12913-020-06010-x"},{"issue":"10","key":"7939_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jclinepi.2012.05.005","volume":"65","author":"ND Shippee","year":"2012","unstructured":"Shippee ND, Shah ND, May CR, Mair FS, Montori VM. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol. 2012;65(10):1041-51. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.05.005","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"7939_CR17","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3(2):e1920622-e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622","journal-title":"JAMA Network Open."},{"key":"7939_CR18","unstructured":"21 C.F.R. \u00a71306.07."},{"key":"7939_CR19","unstructured":"42 C.F.R. \u00a7 8.12."},{"issue":"11","key":"7939_CR20","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamapsychiatry.2020.1511","volume":"77","author":"PJ Joudrey","year":"2020","unstructured":"Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder-decades of effectiveness but still miles away in the US. JAMA Psychiatry. 2020;77(11):1105-1106. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1511","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"7939_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979-981. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0876","journal-title":"JAMA Psychiatry"},{"key":"7939_CR22","doi-asserted-by":"publisher","unstructured":"Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low dose initiation of buprenorphine: a narrative review and practical approach. J Addict Med. 2021;https:\/\/doi.org\/10.1097\/adm.0000000000000945","DOI":"10.1097\/adm.0000000000000945"},{"key":"7939_CR23","doi-asserted-by":"publisher","unstructured":"Sue KL, Cohen S, Tilley J, Yocheved A. A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era. J Addict Med. 2022;https:\/\/doi.org\/10.1097\/adm.0000000000000952","DOI":"10.1097\/adm.0000000000000952"},{"key":"7939_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.socscimed.2014.01.010","volume":"105","author":"R McNeil","year":"2014","unstructured":"McNeil R, Small W, Wood E, Kerr T. Hospitals as a 'risk environment': an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014;105:59-66. https:\/\/doi.org\/10.1016\/j.socscimed.2014.01.010","journal-title":"Soc Sci Med."},{"issue":"1-2","key":"7939_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EP, van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1-2):23-35. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"7939_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/08897077.2018.1439798","volume":"39","author":"N Krawczyk","year":"2018","unstructured":"Krawczyk N, Negron T, Nieto M, Agus D, Fingerhood MI. Overcoming medication stigma in peer recovery: a new paradigm. Subst Abus. 2018;39(4):404-409. https:\/\/doi.org\/10.1080\/08897077.2018.1439798","journal-title":"Subst Abus."},{"issue":"9","key":"7939_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1176\/appi.ajp.2021.20101548","volume":"178","author":"D McCarty","year":"2021","unstructured":"McCarty D, Bougatsos C, Chan B, et al. Office-based methadone treatment for opioid use disorder and pharmacy dispensing: a scoping review. Am J Psychiatry. 2021;178(9):804-817. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20101548","journal-title":"Am J Psychiatry"},{"issue":"14","key":"7939_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.286.14.1724","volume":"286","author":"DA Fiellin","year":"2001","unstructured":"Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. Jama. 2001;286(14):1724-31. https:\/\/doi.org\/10.1001\/jama.286.14.1724","journal-title":"Jama"},{"issue":"1","key":"7939_CR29","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/08897077.2022.2095077","volume":"43","author":"SE Wakeman","year":"2022","unstructured":"Wakeman SE, Lambert E, Kung S, et al. Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts. Substance Abuse.2022;43(1):1317-1321. https:\/\/doi.org\/10.1080\/08897077.2022.2095077","journal-title":"Substance Abuse"},{"issue":"2","key":"7939_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/aog.0000000000004786","volume":"140","author":"SE Wakeman","year":"2022","unstructured":"Wakeman SE, Bryant A, Harrison N. Redefining child protection: addressing the harms of structural racism and punitive approaches for birthing people, dyads, and families affected by substance use. Obstetrics & Gynecology. 2022;140(2):167-173. https:\/\/doi.org\/10.1097\/aog.0000000000004786","journal-title":"Obstetrics & Gynecology."},{"issue":"6","key":"7939_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","volume":"40","author":"B Andraka-Christou","year":"2021","unstructured":"Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff (Millwood). 2021;40(6):920-927. https:\/\/doi.org\/10.1377\/hlthaff.2020.02261","journal-title":"Health Aff (Millwood)."},{"key":"7939_CR32","doi-asserted-by":"publisher","first-page":"940","DOI":"10.15585\/mmwr.mm7129e2","volume":"71","author":"MDN Kariisa","year":"2022","unstructured":"Kariisa M DN, Kumar S, Seth P, Mattson C, Chowdhury F, Jones C. Vital Signs: Drug Overdose Deaths, by Selected Sociodemographic and Social Determinants of Health Characteristics \u2014 25 States and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71:940\u2013947","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"7939_CR33","doi-asserted-by":"publisher","unstructured":"Adams Z KN, Simon R, Sue K, Suen L, Joudrey P. To save lives from opioid overdose deaths, bring methadone into mainstream medicine. Health Affairs Forefront. May 27, 2022. https:\/\/doi.org\/10.1377\/forefront.20220524.911965","DOI":"10.1377\/forefront.20220524.911965"},{"issue":"3","key":"7939_CR34","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.12788\/jhm.3311","volume":"14","author":"H Englander","year":"2019","unstructured":"Englander H, Priest KC, Snyder H, Martin M, Calcaterra S, Gregg J. A call to action: hospitalists' role in addressing substance use disorder. J Hosp Med. 2019;14(3):E1-E4. https:\/\/doi.org\/10.12788\/jhm.3311","journal-title":"J Hosp Med"},{"key":"7939_CR35","doi-asserted-by":"crossref","unstructured":"Englander H, Davis, J.D. Hospital standards of care for people with substance use disorder. New England J of Med. In Press 2022;","DOI":"10.1056\/NEJMp2204687"},{"issue":"6","key":"7939_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.annemergmed.2021.05.024","volume":"78","author":"H Snyder","year":"2021","unstructured":"Snyder H, Kalmin MM, Moulin A, et al. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA Bridge program. Ann Emerg Med. 2021;78(6):759-772. https:\/\/doi.org\/10.1016\/j.annemergmed.2021.05.024","journal-title":"Ann Emerg Med."},{"issue":"3","key":"7939_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1377\/hlthaff.2021.01242","volume":"41","author":"SD Kimmel","year":"2022","unstructured":"Kimmel SD, Rosenmoss S, Bearnot B, et al. Northeast postacute medical facilities disproportionately reject referrals for patients with opioid use disorder. Health Aff (Millwood). 2022;41(3):434-444. https:\/\/doi.org\/10.1377\/hlthaff.2021.01242","journal-title":"Health Aff (Millwood)."},{"issue":"2-3","key":"7939_CR38","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/10550887.2015.1059217","volume":"34","author":"SE Wakeman","year":"2015","unstructured":"Wakeman SE, Rich JD. Addiction treatment within U.S. correctional facilities: bridging the gap between current practice and evidence-based care. J Addict Dis. 2015;34(2-3):220-5. https:\/\/doi.org\/10.1080\/10550887.2015.1059217","journal-title":"J Addict Dis."},{"key":"7939_CR39","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.drugalcdep.2022.109504","volume":"237","author":"BH Lambdin","year":"2022","unstructured":"Lambdin BH, Bluthenthal RN, Tookes HE, et al. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States. Drug and Alcohol Dependence. 2022;237:109504. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109504","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"7939_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamapsychiatry.2021.3716","volume":"79","author":"JB Gibbons","year":"2022","unstructured":"Gibbons JB, Stuart EA, Saloner B. Methadone on wheels\u2014a new option to expand access to care through mobile units. JAMA Psychiatry. 2022;79(3):187-188. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3716","journal-title":"JAMA Psychiatry."},{"key":"7939_CR41","doi-asserted-by":"publisher","first-page":"108483","DOI":"10.1016\/j.jsat.2021.108483","volume":"129","author":"B Chan","year":"2021","unstructured":"Chan B, Hoffman KA, Bougatsos C, Grusing S, Chou R, McCarty D. Mobile methadone medication units: a brief history, scoping review and research opportunity. J Subst Abuse Treat. 2021;129:108483. https:\/\/doi.org\/10.1016\/j.jsat.2021.108483","journal-title":"J Subst Abuse Treat."},{"issue":"1","key":"7939_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/adm.0000000000000739","volume":"15","author":"B Chan","year":"2021","unstructured":"Chan B, Gean E, Arkhipova-Jenkins I, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2021;15(1):74-84. https:\/\/doi.org\/10.1097\/adm.0000000000000739","journal-title":"J Addict Med."},{"issue":"1","key":"7939_CR43","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/08897077.2022.2060447","volume":"43","author":"R Lockard","year":"2022","unstructured":"Lockard R, Priest KC, Gregg J, Buchheit BM. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Subst Abus. 2022;43(1):1150-1157. https:\/\/doi.org\/10.1080\/08897077.2022.2060447","journal-title":"Subst Abus."},{"issue":"1","key":"7939_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","volume":"16","author":"XA Levander","year":"2021","unstructured":"Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):72. https:\/\/doi.org\/10.1186\/s13722-021-00281-3","journal-title":"Addict Sci Clin Pract."},{"key":"7939_CR45","doi-asserted-by":"publisher","first-page":"108655","DOI":"10.1016\/j.jsat.2021.108655","volume":"135","author":"MTH Harris","year":"2022","unstructured":"Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM. \"No home to take methadone to\": experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. J Subst Abuse Treat. 2022;135:108655. https:\/\/doi.org\/10.1016\/j.jsat.2021.108655","journal-title":"J Subst Abuse Treat."},{"key":"7939_CR46","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449. https:\/\/doi.org\/10.1016\/j.jsat.2021.108449","journal-title":"J Subst Abuse Treat."},{"key":"7939_CR47","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68. https:\/\/doi.org\/10.1186\/s13722-021-00275-1","DOI":"10.1186\/s13722-021-00275-1"},{"key":"7939_CR48","doi-asserted-by":"publisher","first-page":"108074","DOI":"10.1016\/j.jsat.2020.108074","volume":"117","author":"N Krawczyk","year":"2020","unstructured":"Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Subs Abuse Treatment. 2020;117:108074. https:\/\/doi.org\/10.1016\/j.jsat.2020.108074","journal-title":"J Subs Abuse Treatment"},{"issue":"2","key":"7939_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/adm.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95-98. https:\/\/doi.org\/10.1097\/adm.0000000000000555","journal-title":"J Addict Med."},{"issue":"4","key":"7939_CR50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/00952990.2019.1605372","volume":"45","author":"RP Winograd","year":"2019","unstructured":"Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. Ame J Drug Alcohol Abuse. 2019;45(4):333-340. https:\/\/doi.org\/10.1080\/00952990.2019.1605372","journal-title":"Ame J Drug Alcohol Abuse"},{"key":"7939_CR51","doi-asserted-by":"publisher","unstructured":"Han BH, Moore AA, Levander XA, To care for older adults with substance use disorder, create age-friendly health systems. Health Affairs Forefront. May 6, 2022. https:\/\/doi.org\/10.1377\/forefront.20220505.917481","DOI":"10.1377\/forefront.20220505.917481"},{"key":"7939_CR52","doi-asserted-by":"publisher","first-page":"108155","DOI":"10.1016\/j.jsat.2020.108155","volume":"120","author":"JD Pytell","year":"2021","unstructured":"Pytell JD, Rastegar DA. Down the drain: reconsidering routine urine drug testing during the COVID-19 pandemic. J Subst Abuse Treat. 2021;120:108155. https:\/\/doi.org\/10.1016\/j.jsat.2020.108155","journal-title":"J Subst Abuse Treat."},{"key":"7939_CR53","doi-asserted-by":"publisher","unstructured":"Gregg J, Hartley J, Lawrence D, Risser A, Blazes C. The naloxone component of buprenorphine\/naloxone: discouraging misuse, but at what cost? J Addict Med. Aug 1 2022;https:\/\/doi.org\/10.1097\/adm.0000000000001030","DOI":"10.1097\/adm.0000000000001030"},{"key":"7939_CR54","doi-asserted-by":"publisher","first-page":"108832","DOI":"10.1016\/j.jsat.2022.108832","volume":"141","author":"M Buresh","year":"2022","unstructured":"Buresh M, Nahvi S, Steiger S, Weinstein ZM. Adapting methadone inductions to the fentanyl era. J Subst Abuse Treat. 2022;141:108832. https:\/\/doi.org\/10.1016\/j.jsat.2022.108832","journal-title":"J Subst Abuse Treat."},{"issue":"7","key":"7939_CR55","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1377\/hlthaff.2019.00056","volume":"38","author":"JL Gregg","year":"2019","unstructured":"Gregg JL. Dying to access methadone. Health Aff (Millwood). 2019;38(7):1225-1227. https:\/\/doi.org\/10.1377\/hlthaff.2019.00056","journal-title":"Health Aff (Millwood)."},{"key":"7939_CR56","doi-asserted-by":"publisher","unstructured":"Collins D, Alla J, Nicolaidis C, et al. \"If it wasn't for him, I wouldn't have talked to them\": qualitative study of addiction peer mentorship in the hospital. J Gen Intern Med. 2019;12:12:https:\/\/doi.org\/10.1007\/s11606-019-05311-0","DOI":"10.1007\/s11606-019-05311-0"},{"issue":"1","key":"7939_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/adm.0000000000000810","volume":"16","author":"E Stack","year":"2022","unstructured":"Stack E, Hildebran C, Leichtling G, et al. Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings - a narrative review. J Addict Med. 2022;16(1):93-100. https:\/\/doi.org\/10.1097\/adm.0000000000000810","journal-title":"J Addict Med"},{"issue":"6","key":"7939_CR58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMc2015435","volume":"383","author":"AH Kral","year":"2020","unstructured":"Kral AH, Lambdin BH, Wenger LD, Davidson PJ. Evaluation of an unsanctioned safe consumption site in the United States. N Engl J Med. 2020;383(6):589-590. https:\/\/doi.org\/10.1056\/NEJMc2015435","journal-title":"N Engl J Med"},{"key":"7939_CR59","doi-asserted-by":"publisher","unstructured":"Platt L, Reed J, Minozzi S, et al. Effectiveness of needle\/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. Cochrane Database Syst Rev. 2016;2016(1) https:\/\/doi.org\/10.1002\/14651858.Cd012021","DOI":"10.1002\/14651858.Cd012021"},{"issue":"1","key":"7939_CR60","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.amepre.2019.08.012","volume":"58","author":"HN Virani","year":"2020","unstructured":"Virani HN, Haines-Saah RJ. Drug decriminalization: a matter of justice and equity, not just health. Am J Prev Med. 2020;58(1):161-164. https:\/\/doi.org\/10.1016\/j.amepre.2019.08.012","journal-title":"Am J Prev Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-022-07939-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-022-07939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:04:17Z","timestamp":1700265857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-022-07939-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7939"],"URL":"https:\/\/doi.org\/10.1007\/s11606-022-07939-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}